These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 11930693)

  • 1. [Study on the reversion of drug resistance in human cervical cancer cell lines].
    Chen H; Chen H; Wu X
    Zhonghua Fu Chan Ke Za Zhi; 2001 Nov; 36(11):669-71. PubMed ID: 11930693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of the interactions of SDZ PSC 833 ([3'-keto-Bmt1]-Val2]-Cyclosporine), a multidrug resistance modulator, with P-glycoprotein.
    Archinal-Mattheis A; Rzepka RW; Watanabe T; Kokubu N; Itoh Y; Combates NJ; Bair KW; Cohen D
    Oncol Res; 1995; 7(12):603-10. PubMed ID: 8704277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Piperine (PP) enhanced mitomycin-C (MMC) therapy of human cervical cancer through suppressing Bcl-2 signaling pathway via inactivating STAT3/NF-κB.
    Han SZ; Liu HX; Yang LQ; Cui LD; Xu Y
    Biomed Pharmacother; 2017 Dec; 96():1403-1410. PubMed ID: 29169726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of SDZ PSC 833 ([3'-keto-Bmt1]-[Val2]-cyclosporin) on serum protein binding and distribution to blood cells of doxorubicin, vincristine and etoposide in vitro.
    Watanabe T; Iwasaki M; Todaka T; Morikawa H; Ohtawa M
    Anticancer Drugs; 1997 Apr; 8(4):400-4. PubMed ID: 9180396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833.
    Boesch D; Gavériaux C; Jachez B; Pourtier-Manzanedo A; Bollinger P; Loor F
    Cancer Res; 1991 Aug; 51(16):4226-33. PubMed ID: 1678313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism of the reversal effect of mifepristone on drug resistance of the human cervical cancer cell line HeLa/MMC.
    Chen H; Duan J; Zuo F
    Genet Mol Res; 2014 Feb; 13(1):1288-95. PubMed ID: 24634186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Restoration of taxol sensitivity of multidrug-resistant cells by the cyclosporine SDZ PSC 833 and the cyclopeptolide SDZ 280-446.
    Jachez B; Nordmann R; Loor F
    J Natl Cancer Inst; 1993 Mar; 85(6):478-83. PubMed ID: 8095304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteasomal inhibition sensitizes cervical cancer cells to mitomycin C-induced bystander effect: the role of tumor microenvironment.
    Singh SV; Ajay AK; Mohammad N; Malvi P; Chaube B; Meena AS; Bhat MK
    Cell Death Dis; 2015 Oct; 6(10):e1934. PubMed ID: 26492368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytotoxicity and apoptosis enhancement in breast and cervical cancer cells upon coadministration of mitomycin C and essential oils in nanoemulsion formulations.
    Al-Otaibi WA; Alkhatib MH; Wali AN
    Biomed Pharmacother; 2018 Oct; 106():946-955. PubMed ID: 30119267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Evaluation of a new anti-cancer drug regimen against uterine cervical cancer in nude mice].
    Fushiki H; Hidaka T; Hori S; Fujimura M; Yamakawa Y; Izumi R
    Gan To Kagaku Ryoho; 1997 Oct; 24(13):1981-5. PubMed ID: 9350246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overcoming PGP-related multidrug resistance. The cyclosporine derivative SDZ PSC 833 can abolish the resistance to methoxy-morpholynil-doxorubicin.
    Michieli M; Damiani D; Michelutti A; Melli C; Ermacora A; Geromin A; Fanin R; Russo D; Baccarani M
    Haematologica; 1996; 81(4):295-301. PubMed ID: 8870372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New multidrug-resistance-reversing drugs, MS-209 and SDZ PSC 833.
    Naito M; Tsuruo T
    Cancer Chemother Pharmacol; 1997; 40 Suppl():S20-4. PubMed ID: 9272129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose-dependent brain penetration of SDZ PSC 833, a novel multidrug resistance-reversing cyclosporin, in rats.
    Lemaire M; Bruelisauer A; Guntz P; Sato H
    Cancer Chemother Pharmacol; 1996; 38(5):481-6. PubMed ID: 8765444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of mitomycin C and carboplatin pretreatment on multidrug resistance-associated P-glycoprotein expression and on subsequent suppression of tumor growth by doxorubicin and paclitaxel in human metastatic breast cancer xenografted nude mice.
    Ihnat MA; Nervi AM; Anthony SP; Kaltreider RC; Warren AJ; Pesce CA; Davis SA; Lariviere JP; Hamilton JW
    Oncol Res; 1999; 11(7):303-10. PubMed ID: 10757444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antineoplastic activity of mitomycin C formulated in nanoemulsions-based essential oils on HeLa cervical cancer cells.
    Alkhatib MH; Al-Otaibi WA; Wali AN
    Chem Biol Interact; 2018 Aug; 291():72-80. PubMed ID: 29908166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atypical multi-drug resistance (MDR): low sensitivity of a P-glycoprotein-expressing human T lymphoblastoid MDR cell line to classical P-glycoprotein-directed resistance-modulating agents.
    Jachez B; Loor F
    Anticancer Drugs; 1993 Dec; 4(6):605-15. PubMed ID: 7905300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study.
    Sonneveld P; Marie JP; Huisman C; Vekhoff A; Schoester M; Faussat AM; van Kapel J; Groenewegen A; Charnick S; Zittoun R; Löwenberg B
    Leukemia; 1996 Nov; 10(11):1741-50. PubMed ID: 8892677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intracellular delivery of mitomycin C with targeted polysaccharide conjugates against multidrug resistance.
    Cao Y; Chen D; Zhao P; Liu L; Huang X; Qi C; Liu Y; He H; Wang Q; Liu Y; Chen S
    Ann Biomed Eng; 2011 Sep; 39(9):2456-65. PubMed ID: 21701935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytotoxic activity of cyclosporin A and [3-keto-Bmt1]-[Val2]-cyclosporin (SDZ PSC 833) on tumour cells from patients with haematological malignancies.
    Martinsson P; Nygren P; Fridborg H; Nilsson K; Kristensen J; Larsson R
    Eur J Clin Pharmacol; 1997; 52(3):199-203. PubMed ID: 9218926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting tumor responses to mitomycin C on the basis of DT-diaphorase activity or drug metabolism by tumor homogenates: implications for enzyme-directed bioreductive drug development.
    Phillips RM; Burger AM; Loadman PM; Jarrett CM; Swaine DJ; Fiebig HH
    Cancer Res; 2000 Nov; 60(22):6384-90. PubMed ID: 11103802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.